Suppr超能文献

日本心房颤动患者导管消融后的主要不良心血管事件和死亡率:伏见 AF 登记研究。

Major adverse cardiovascular events and mortality after catheter ablation in Japanese patients with atrial fibrillation: The Fushimi AF Registry.

机构信息

Department of Cardiology, Heart Rhythm Section, Ogaki Tokushukai Hospital, 6-85-1, Hayashimachi, Ogaki, 503-0015, Japan.

Department of Cardiology, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan.

出版信息

Heart Vessels. 2021 Aug;36(8):1219-1227. doi: 10.1007/s00380-021-01796-0. Epub 2021 Feb 11.

Abstract

BACKGROUND

The impact of catheter ablation (CA) on the long-term clinical outcomes in atrial fibrillation (AF) are unclear due to limited cohort investigations.

METHODS

The Fushimi AF Registry is a community-based prospective survey of patients with AF in Fushimi-ku, Kyoto, Japan. Of 4465 patients enrolled between March 2011 and July 2019, analyses were performed on 2639 patients (492 patients who underwent CA and 2147 patients who received standard rhythm- and/or rate-control drug therapy at baseline). We compared the baseline characteristics and the incidence of major adverse cardiovascular events (MACE: the composite of cardiovascular death, heart failure hospitalization, myocardial infarction, ischemic stroke or systemic embolism), and all-cause mortality during the follow-up using propensity score matching.

RESULTS

After entering 20 covariates in the current matching analysis, 342 patients who underwent CA and 342 matched patients who received drug therapy, with a median follow-up of 1865 days, were included. The patients who underwent CA were significantly associated with lower incidence of MACE (hazard ratio (HR) 0.56, 95% confidential interval (CI) 0.36-0.86; P = 0.0077), and all-cause mortality (HR 0.47, 95% CI 0.29-0.75; P = 0.0016).

CONCLUSION

CA was associated with lower incidences of MACE and all-cause mortality for patients with AF as compared with those who received drug therapy. The most common event of MACE in patients who underwent CA was heart failure hospitalization.

CLINICAL TRIAL REGISTRATION

URL: http://www.umin.ac.jp/ctr/index.htm UNIQUE IDENTIFIER: UMIN000005834.

摘要

背景

由于有限的队列研究,导管消融 (CA) 对心房颤动 (AF) 长期临床结局的影响尚不清楚。

方法

伏见 AF 注册研究是一项针对日本京都府伏见区 AF 患者的基于社区的前瞻性调查。在 2011 年 3 月至 2019 年 7 月期间,共纳入 4465 例患者,其中 2639 例患者(492 例行 CA 治疗,2147 例患者在基线时接受标准节律和/或心率控制药物治疗)进行了分析。我们使用倾向评分匹配比较了基线特征和主要不良心血管事件(MACE:心血管死亡、心力衰竭住院、心肌梗死、缺血性卒中和全身性栓塞的复合终点)发生率以及随访期间的全因死亡率。

结果

在当前匹配分析中纳入 20 个协变量后,共纳入 342 例接受 CA 治疗的患者和 342 例接受药物治疗的匹配患者,中位随访时间为 1865 天。与接受药物治疗的患者相比,接受 CA 治疗的患者 MACE(风险比(HR)0.56,95%置信区间(CI)0.36-0.86;P = 0.0077)和全因死亡率(HR 0.47,95% CI 0.29-0.75;P = 0.0016)的发生率显著降低。

结论

与接受药物治疗的患者相比,CA 治疗可降低 AF 患者的 MACE 和全因死亡率。接受 CA 治疗的患者最常见的 MACE 事件是心力衰竭住院。

临床试验注册

网址:http://www.umin.ac.jp/ctr/index.htm 唯一识别码:UMIN000005834。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验